Using genetic and epigenetic analyses coupled with
powerful perturbation technologies to test gene functions in human cells and mouse
models, we hope to identify the critical drivers of this disease and the basis for
therapeutic responses.
Modeling mRNA expression heterogeneity in tumors through bimodal profiles is a novel
powerful approach with the potential to uncover
therapeutic targets that benefit subsets of cancer patients.